echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Moderna initiates phase III clinical recruitment of 6900 subjects for cytomegalovirus mRNA vaccine

    Moderna initiates phase III clinical recruitment of 6900 subjects for cytomegalovirus mRNA vaccine

    • Last Update: 2021-11-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Shi Bei

    On October 20, Moderna registered the efficacy, safety and immunogen of its cytomegalovirus (CMV) mRNA vaccine mRNA-1647 in 16-40 year old female healthy subjects on the US clinical trial website (ClinicalTrials.


    The study plans to recruit 6900 subjects.


    The mRNA-1647 developed by Moderna contains 6 mRNA sequences, including 5 mRNA encoding the pentamer complex and 1 mRNA encoding the gB antigen


    Unlike protein-based vaccines, mRNA-1647 refers to the production and production of functional antigens by the body's own cells, which mimic the antigens presented by CMV to the immune system during natural infection


    Cytomegalovirus (CMV) is a common pathogen that belongs to the herpes virus family


    CMV infection is common in young children who have never been exposed to the virus, and is acquired and spread through contact with saliva, breast milk, mucus, and urine


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.